ARA Portfolio Management Company L.L.C.

AMT, VNO, ADM, HCP, SID, ACOR Expected To Be Lower After Earnings Releases on Tuesday.
M2 Presswire; 10/30/2009; 3734 words; ...pulse of a company four times...vitality of that company. This technology...identify those companies that seem...releases for that company. It combines...Rental and Management segment engages...company had a portfolio of approximately...Washington D.C. and ...

At deadline.(investments of California. Public Employees' Retirement System)(Royal Cosun hires AXA Investment Managers)(surveys of 401k plans)
Pensions & Investments; 10/1/2007; 1570 words; ...into the ARA Asia Dragon...investment management of nearly...Lynch. Duke Management also runs...option. Company contributions...Investment Management Board hired...million from L.A. City...Chairman Edward C. "Ned...duration bond portfolio, said Katie...

Xanthus Presents Phase 2 Data Showing Xanafide is Associated with Complete Remissions in Secondary AML.(Clinical report)
Business Wire; 6/2/2007; 1357 words; ...results from the Company's Phase 2 study...Xanafide and ara-C was associated...standard dose of ara-C as a continuous...said Robert L. Capizzi, M...developing a portfolio of novel, clinical...candidates through a management team whose accomplished...

Xanthus Completes Enrollment of Phase 2 Trial of Xanafide for the Treatment of Secondary AML.
Business Wire; 12/4/2006; 1028 words; ...drug development company, today announced...stated Robert L. Capizzi, M...standard dose of ara-C as a continuous...amonafide and ara-C exhibited particularly...developing a portfolio of novel, clinical...candidates through a management team whose accomplished...

Callisto CEO Dr. Gary S. Jacob Releases Letter to Shareholders; CEO Affirms Commitment to Continued Aggressive Development of Clinical Programs with Atiprimod and L-Annamycin Anti-cancer Agents.
Business Wire; 4/11/2006; 1936 words; ...outlines the Company's significant...primary focus of management's attention...Atiprimod and L-Annamycin...Progress with L-Annamycin...trial with L-Annamycin...combination with Ara-C) in adult...developing a robust portfolio of anti-cancer...